DBV Technologies S.A. $DBVT Shares Sold by Redmile Group LLC

Redmile Group LLC reduced its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 10.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 491,340 shares of the company’s stock after selling 58,500 shares during the quarter. DBV Technologies accounts for about 0.7% of Redmile Group LLC’s investment portfolio, making the stock its 22nd largest holding. Redmile Group LLC owned about 0.83% of DBV Technologies worth $10,264,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Diversify Wealth Management LLC acquired a new stake in DBV Technologies in the first quarter valued at $1,293,000. Elmind Capital LP acquired a new position in DBV Technologies during the 1st quarter worth $5,536,000. UBS Group AG grew its holdings in DBV Technologies by 165,347.3% during the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock worth $4,694,000 after acquiring an additional 244,714 shares in the last quarter. Dorsey Wright & Associates bought a new stake in shares of DBV Technologies in the 1st quarter worth about $2,142,000. Finally, Polymer Capital Management HK LTD bought a new stake in shares of DBV Technologies in the 4th quarter worth about $1,236,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Trading Down 2.9%

Shares of NASDAQ:DBVT opened at $13.50 on Wednesday. DBV Technologies S.A. has a 52 week low of $8.51 and a 52 week high of $26.18. The firm has a market capitalization of $799.34 million, a P/E ratio of -3.85 and a beta of -0.95. The firm’s 50 day moving average is $16.35 and its two-hundred day moving average is $19.26.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.90 million. Analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Citizens Jmp upped their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. Finally, Guggenheim reiterated a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DBV Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.